Mavyret

This Small Biotech Is Building on a Surprising Success
This Small Biotech Is Building on a Surprising Success
Motley Fool
AbbVie
Mavyret
Enanta Pharmaceuticals
glecaprevir
hepatitis C
Flag link:
5 Must-See Quotes From AbbVie's Management
5 Must-See Quotes From AbbVie's Management
Yahoo/Motley Fool
AbbVie
Humira
hepatitis C
Mavyret
Viekira
M&A
Flag link:
Dogged by AbbVie's new share-stealing Mavyret, Gilead's hep C forecast comes in far short
Dogged by AbbVie's new share-stealing Mavyret, Gilead's hep C forecast comes in far short
Fierce Pharma
AbbVie
Mavyret
Gilead Sciences
hepatitis C
Harvoni
Sovaldi
Flag link:
5 Highest-Growth Drugs of 2018 -- and Who Will Get Rich from Them
5 Highest-Growth Drugs of 2018 -- and Who Will Get Rich from Them
Motley Fool
Merck
Keytruda
AbbVie
Humira
Mavyret
Bristol-Myers Squibb
Eliquis
Pfizer
Ibrance
Flag link:
There's a Lot to Like in AbbVie's Q3 Update
There's a Lot to Like in AbbVie's Q3 Update
Motley Fool
AbbVie
earnings
Humira
Imbruvica
Mavyret
Flag link:
AbbVie’s new, cheaper hepatitis C drug could launch the drug world’s own Hunger Games
AbbVie’s new, cheaper hepatitis C drug could launch the drug world’s own Hunger Games
Marketwatch
AbbVie
hepatitis C
Mavyret
Gilead Sciences
Merck
Flag link:
Is AbbVie About to Deliver a Blow to Gilead Sciences' Guidance?
Is AbbVie About to Deliver a Blow to Gilead Sciences' Guidance?
Motley Fool
AbbVie
Gilead Sciences
hepatitis C
Mavyret
Flag link:
AbbVie's new pan-genotypic hepatitis C drug Mavyret deeply underprices the competition
AbbVie's new pan-genotypic hepatitis C drug Mavyret deeply underprices the competition
Fierce Pharma
AbbVie
hepatitis C
Mavyret
drug pricing
Flag link: